Immutep Ltd (AU:IMM) has released an update.
Immutep Limited reported an increase in its annual loss to $42.7 million, primarily due to a $5.3 million rise in R&D and clinical trial costs. Despite the higher loss, the company saw a boost in other income and an increase in interest income due to better cash management and higher interest rates. No dividends were paid or declared, and the company’s net tangible asset backing per share improved slightly from the previous year.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
